This week, we talk about new treatments for wet dry age-related macular degeneration (AMD) with Judith Greciet, CEO of PulseSight Therapeutics, and there’s a conversation with Maite Agüeros, CEO and co-founder of InnoUp Farma about, among other things, peanut allergies.
Interview times:
03:24 PulseSight
20:43 InnoUp
Tackling dry AMD
PulseSight Therapeutics SAS, an ophthalmology biotech company developing non-viral vectorised therapies with minimally-invasive delivery technology, recently announced the first patient has been successfully dosed in its phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead programme, PST-611, in humans.
PST-611 is a first-in-class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA), expressing human transferrin, a highly potent iron regulator, playing a central role in restoring normal iron homeostasis.
AMD is the leading cause of central vision loss in the elderly, affecting 200m people worldwide. AMD's pathogenesis is complex, and the disease still represents a high unmet medical need. Dry AMD involves the dysregulation of iron homeostasis, leading to an excess of free iron causing highly toxic effects such as inflammation, oxidative stress, and ultimately retinal cell death (ferroptosis).
PST-611-CT1 is a first-in-human single ascending dose study that aims to establish, in six to a maximum of 12 dry AMD/GA patients, the safety profile of the drug and validate the maximal tolerated dose in view of the following phase IIa proof-of-concept trial. Preliminary results are anticipated early 2026, subject to patient recruitment.
Our conversation is with Judith Greciet, CEO of PulseSight Therapeutics.
New ways to treat peanut allergies
InnoUp is a clinical stage company specialising in nanotechnology innovations and developing oral drug delivery solutions. It has developed a Nanoparticle Platform that is protected by international patents.
InnoUp has two programmes currently in the clinical stage: an oral peanut allergy vaccine (INP20) and an oral Paclitaxel to treat breast cancer (INP12).
We have a conversation with Maite Agüeros, CEO and co-founder of InnoUp.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Are You A Charlotte?
In 1997, actress Kristin Davis’ life was forever changed when she took on the role of Charlotte York in Sex and the City. As we watched Carrie, Samantha, Miranda and Charlotte navigate relationships in NYC, the show helped push once unacceptable conversation topics out of the shadows and altered the narrative around women and sex. We all saw ourselves in them as they searched for fulfillment in life, sex and friendships. Now, Kristin Davis wants to connect with you, the fans, and share untold stories and all the behind the scenes. Together, with Kristin and special guests, what will begin with Sex and the City will evolve into talks about themes that are still so relevant today. "Are you a Charlotte?" is much more than just rewatching this beloved show, it brings the past and the present together as we talk with heart, humor and of course some optimism.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.